Covance Receives MHRA Accreditation for UK Facility
July 30, 2009, Princeton, NJ
The Medicines and Healthcare products Regulatory Agency (MHRA) awarded Covance's (Princeton, NJ) clinical research unit in Leeds, UK, where the company conducts first-in-human studies, with standard and supplementary accreditation for the conduct of clinical pharmacology in Europe. The MHRA accreditation, which is voluntary, ensures that research facilities and studies meet industry standards for patient safety in early clinical development.
"Covance delivers the highest level of data quality and safety for first-in-human trials, which is confirmed by the accreditation," said Rob Aspbury, MD, Covance's managing director of clinical research services, in a press release.
In order to receive this type of accreditation, formal inspections are performed by MHRA, which is based in London.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
